Files and links (1)
https://menopause.org/wp-content/uploads/2024/09/2024-Oral-and-Poster-Presentation-Abstracts.pdf#page=33
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Conference paper
Effects of the Vaginal Suppository Revaree® Plus on Women Who Experience Moderate-to-Severe Vaginal Dryness
P-69
Sep 2024
Abstract
Objective: The primary objective was to evaluate the effects of the nonhormonal moisturizing agent Revaree Plus, containing hyaluronic acid (HA) and sweet almond oil, on vaginal symptoms in women who experience moderate-to-severe vaginal dryness.
Design: In an open-label study, women aged 41-79 with self-reported moderate-to-severe vaginal dryness inserted a Revaree Plus vaginal suppository, which contains 10 mg of HA and sweet almond oil, twice a week for four weeks. This new formulation, which contains double the amount of HA as in Revaree 5 mg, was evaluated for its impact on vaginal symptoms including dryness (internal and vulvar), itching, burning or stinging, irritation, and painful sex. Primary outcome: change in vaginal dryness via weekly diaries. Secondary outcomes: validated monthly questionnaires (Vaginal Symptom Questionnaire [VSQ] and Day-to-Day Impact of Vaginal Aging [DIVA]) at Baseline and Week 4. Data was analyzed using Group x Time Repeated Measures ANOVA (alpha < 0.05).
Results: Seventy women (57.3 ± 7.5 years) completed four weeks of treatment. Sixty-three women were postmenopausal, five were perimenopausal, and two were premenopausal. After one week, over half of the women showed an improvement in vaginal dryness (n=65), burning or stinging (n=28), and irritation (n=32) by at least one category (e.g., from severe to moderate or moderate to absent). Moreover, 43% of women experienced a decrease in painful sex after one week of usage (n=44). After four weeks, approximately 80% of women showed an improvement in vaginal dryness by at least one category (n=70). There were no serious adverse events reported. Consumer experience data provides support for Revaree Plus as a comfortable, easy to use, and efficacious treatment for vaginal dryness. 90% of women were satisfied with Revaree Plus (n=69). Over 90% of women agreed that the product reduced their vaginal dryness and improved their daily comfort (n=69). Additionally, 93% of women would recommend Revaree Plus (n=69), and 95% of women preferred it to other products on the market for vaginal dryness (n=56). The full results are detailed in Tables 1 and 2.
Conclusion: The fourweek usage of Revaree Plus, a nonhormonal moisturizing agent with HA and sweet almond oil, resulted in a significant improvement in vaginal dryness. Improvement was seen across other bothersome vaginal symptoms including vulvar dryness, itching, burning or stinging, and irritation. Additionally, Revaree Plus was shown to significantly alleviate vaginal pain and dryness during sexual intercourse. There was a positive effect of the vaginal suppository on quality-of-life metrics such as activities of daily living, emotional well-being, sexual functioning, and body image. Lastly, 90% of women were satisfied with Revaree Plus and would recommend the product to others. These findings provide support for the use of Revaree Plus to reduce vaginal dryness in women.
Metrics
1721 Record Views
Details
- Title
- Effects of the Vaginal Suppository Revaree® Plus on Women Who Experience Moderate-to-Severe Vaginal Dryness
- Creators
- Susan Kellogg-Spadt - Drexel University, Obstetrics and GynecologyTatiana Silva - Bonafide Health (United States, Harrison)Michael Krychman - University of California, IrvineSuzanne Weber - AdventHealth Medical Group (USA, Littleton)Alyssa Dweck - Bonafide Health (United States, Harrison)Trisha A Van Dusseldorp - Bonafide Health (United States, Harrison)James Komorowski - Bonafide Health (United States, Harrison)
- Publication Details
- P-69
- Conference
- 2024 Annual Meeting of The Menopause Society (Chicago, Illinois, United States, 10 Sep 2024–14 Sep 2024)
- Publisher
- The Menopause Society
- Number of pages
- 1
- Grant note
- Sources of Funding: Bonafide Health, LLC
- Resource Type
- Conference paper
- Language
- English
- Academic Unit
- Obstetrics and Gynecology
- Other Identifier
- 991021903710004721